Mitapivat
Non-Transfusion-dependent Beta-Thalassemia
Agios Pharmaceuticals, Inc.Small moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Non-Transfusion-dependent Beta-Thalassemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Sodium 2,2 Dimethylbutyrate Boston University | Phase 2 | B |
Vit-2763 Twice A Day Vifor (International) Inc. | Phase 2 | B |
Hydroxyurea Shiraz University of Medical Sciences | Phase 2 | B |
Vit-2763 Once A Day Vifor (International) Inc. | Phase 2 | B |
L-Carnitine Shiraz University of Medical Sciences | Phase 2 | B |
View all 11 →
Same molecule, other indications
Mitapivat is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →